ArticleHaematologica2020
Rapid generation of multivirus-specific T lymphocytes for the prevention and treatment of respiratory viral infections.
5 registry-linked trialsOpen access · goldAbstract read
In one paragraph
Article in Haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT04933968 phase1 / phase2terminatednot on this mapstarted 2022, after this paper: background citation
Phase 1/2, Double-Blind, Placebo-Controlled, Dose Escalation and Expansion Study of ALVR106 in Addition to Standard of Care for the Treatment of High-Risk Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant
NCT07638332 phase1 / phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation
A Single-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Efficacy of LB-DTK-BKV in Patients With BK Virus-Associated Hemorrhagic Cystitis Following Allogeneic Hematopoietic Stem Cell Transplantation in Children, Adolescents, and Adults
NCT07670468 phase1 / phase2recruitingnot on this mapstarted 2025, after this paper: background citation
A Single-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoietic Stem Cell Transplantation.
An Exploratory Clinical Study of Autologous LB-DTK-CMV in Patients With Antiviral-Resistant and Refractory Cytomegalovirus Retinitis.
A Prospective Clinical Study to Evaluate the Safety and Efficacy of Virus Specific T-Cell Administration in Pediatric Patients With Systemic Viral Infection Following Allogeneic Hematopoietic Stem Cell Transplantation.
Who cites it
21 citing papers in PubMed, 36 citations in OpenAlex.
- Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Trial
- Live Attenuated Influenza Virus as a Vector for Multivalent T-Cell Vaccines: Targeting RSV, hMPV, and PIV3.Vaccines · 2026Article
- Respiratory Virus Infections and Pulmonary Impairment After Allogeneic Hematopoietic Cell Transplantation.The Journal of infectious diseases · 2026Article
- Virus-Specific T-Cell Therapy for the Management of Viral Infections in the Immunocompromised.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2025Review
- Cell therapies for viral diseases: a new frontier.Seminars in immunopathology · 2025Review
- Are any specific respiratory viruses more severe than others in recipients of allogeneic stem cell transplantation? A focus on lower respiratory tract disease.Bone marrow transplantation · 2024Article
- Respiratory infections predominate after day 100 following B-cell maturation antigen-directed CAR T-cell therapy.Blood advances · 2023Article
- A method for polyclonal antigen-specific T cell-targeted genome editing (TarGET) for adoptive cell transfer applications.Molecular therapy. Methods & clinical development · 2023Article
- Structural basis for respiratory syncytial virus and human metapneumovirus neutralization.Current opinion in virology · 2023Review
- Pre-existing immunity does not impair the engraftment of CRISPR-Cas9-edited cells in rhesus macaques conditioned with busulfan or radiation.Molecular therapy. Methods & clinical development · 2023Article
- Article
- Pathogen-specific T Cells: Targeting Old Enemies and New Invaders in Transplantation and Beyond.HemaSphere · 2023Review
- Generation of Cytotoxic T Cells and Dysfunctional CD8 T Cells in Severe COVID-19 Patients.Cells · 2022Article
- In Vitro Generation of BK polyomavirus-specific T cells for adoptive cell therapy in refractory cystitis hemorrhagic patients after hematopoietic stem cell transplantation.BMC immunology · 2022Article
- The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Review
- Cellular Immunotherapy and the Lung.Vaccines · 2021Review
- Reinforcing the Immunocompromised Host Defense against Fungi: Progress beyond the Current State of the Art.Journal of fungi (Basel, Switzerland) · 2021Review
- Host-virus interaction and viral evasion.Cell biology international · 2021Review
- Review
- Evaluation of Risk Factors for Exacerbations in Children with Adenoviral Pneumonia.BioMed research international · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Spyridoula VasileiouCenter for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA.
Anne M TurneyCenter for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA.
Manik KuvalekarCenter for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA.
Shivani S MukhiCenter for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA.
Ayumi WatanabeCenter for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA.
Premal LullaCenter for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA.
Carlos A RamosCenter for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA.
Swati NaikCenter for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA.
Juan F VeraCenter for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA.
Ifigeneia TzannouCenter for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA.
Ann M LeenCenter for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA amleen@txch.org.
Baylor College of Medicine · USMethodist Hospital · USTexas Children's Hospital · USHouston Methodist · US
Funding
Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI DAVID R ROWLEY · 2007 to 2026
$73.9MNCI NIH HHS P30 CA125123
Abstract
PubMed holds no abstract for this paper.
Indexed as
T-Lymphocytes, CytotoxicVirus DiseasesCD8-Positive T-LymphocytesCytomegalovirusHumans
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
NCT04933968ClinicalTrials.gov
NCT07638332ClinicalTrials.gov
NCT07670468ClinicalTrials.gov
NCT07679412ClinicalTrials.gov
NCT07685457ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.